At BioIntelliSense, we’re helping to build the blueprint for the future of tech-enabled healthcare. Today, the FDA-cleared BioButton® wearable device is continuously monitoring over 100K patients, enabling clinicians to automate vital sign collection and to enable better, safer care from in-hospital to home. BioIntelliSense CEO James Mault, MD, FACS and CCO Carolyn Walsh recently contributed their industry expertise and key learnings to help shape the Consumer Technology Association’s newest #telehealth guidelines.
Today, the Consumer Technology Association published the 30th ( 🎉 ) #digitalhealth standard in our portfolio, CTA-2113 - Best Practices and Recommendations for Telehealth Solutions. This standard offers a comprehensive framework for integrating telehealth solutions into the healthcare system, for various use cases such as acute care, post-acute care, chronic care, and telehealth visits. CTA-2113 covers topics like simplicity, accuracy, privacy, cybersecurity, artificial intelligence, and data-driven decision making. It also helps overcome the barriers and challenges of implementing and scaling telehealth solutions, such as technological, regulatory, and organizational issues. Many thanks to the R11 WG 14 - Telehealth for the development of this important work and specifically James Mault, MD, FACS and Carolyn Walsh for their leadership! Download CTA-2113 here: https://lnkd.in/gAvcTgvk.